Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Beam Therapeutics (BEAM) Research & Development (2019 - 2025)

Beam Therapeutics (BEAM) has disclosed Research & Development for 7 consecutive years, with $99.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Research & Development fell 2.14% to $99.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $409.6 million, a 11.44% increase, with the full-year FY2025 number at $409.6 million, up 11.44% from a year prior.
  • Research & Development was $99.3 million for Q4 2025 at Beam Therapeutics, down from $109.8 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $190.1 million in Q1 2021 to a low of $45.6 million in Q2 2021.
  • A 5-year average of $95.7 million and a median of $97.2 million in 2021 define the central range for Research & Development.
  • Peak YoY movement for Research & Development: soared 782.2% in 2021, then crashed 65.59% in 2022.
  • Beam Therapeutics' Research & Development stood at $96.8 million in 2021, then dropped by 10.79% to $86.3 million in 2022, then soared by 62.24% to $140.1 million in 2023, then dropped by 27.58% to $101.4 million in 2024, then decreased by 2.14% to $99.3 million in 2025.
  • Per Business Quant, the three most recent readings for BEAM's Research & Development are $99.3 million (Q4 2025), $109.8 million (Q3 2025), and $101.8 million (Q2 2025).